Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

EGFR Mutations and Acquired Resistance After Responding

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

Thus far, the vast majority of patients who have an initial response to EGFR tyrosine kinase inhibitors like Iressa and Tarceva will eventually become resistant to them. At this year’s ASCO, our huge annual US-based oncology conference, a report was made by the group at Memorial Sloan Kettering Cancer Center (Riely abstract here) on a small series of patients who had progressed after a prolonged period of responding to Iressa or Tarceva. They found that patients who had slow progression, generally without symptoms, and then came off of their EGFR TKI therapy would often experience a rapid worsening of symptoms.

In general, we don’t continue drugs on which patients are showing progression, because we consider the drug ineffective at that point, but in this case it could just be a less effective set of brakes that is still better than not having them. In some cases in oncology, we do routinely continue drugs after patients have shown progression, such as men who initially responded to hromone therapy for prostate cancer and then continue on hormore therapy, or women with breast cancer who progress on chemo with Herceptin and are then often put on another chemo approach with Herceptin. We really don’t know the best way to manage situations like this. The early evidence suggests that approximately half of the patients with an initial response to EGFR TKIs who then progress seem to develop a defined mutation, called T790M, that makes drugs like Tarceva no longer fit as well as it previously did to the EGFR target protein. At this point, it is not clear if there is a way to reverse that process and have patients respond again to EGFR inhibitors. In lab models, some “irreversible” inhibitors of EGFR, such as a drug made by WYeth that goes by the catchy name HKI-272, seems to have encouraging activity in the test tube models. It is being tested in patients at a few centers around the country right now. The new agent Tykerb (lapatinib), which blocks both EGFR and another receptor in the same family known as HER-2 and has demonstrated activity in patients with breast cancer who have been previously treated, may bind to EGFR anfter it develops the secondary mutation. Still, at this point we haven’t seen how these and other potentially helpful drugs perform in real people who have stopped responding to drugs like Tarceva or Iressa. A further complicating factor is the evidence thus far that adding chemo and drugs like Iressa or Tarceva at the same time may lead to antagonism of each other, which would make it problematic to just add new chemo while keeping the EGFR TKI therapy ongoing. Perhaps adding the anti-angiogenesis agent Avastin or another agent targeting EGFR like cetuximab (an IV monoclonal antibody against EGFR) can be combined with EGFR TKIs and improve results, but at this point nobody has a clear answer of a best way to proceed in these cases.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
Article
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 

Forum Discussions

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
 Hi arm2966, Welcome to…
By JanineT GRACE … on
Joanne indwelling catheters
By arm2966 on
Hi and welcome to Grace. …
By JanineT GRACE … on
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on